Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast Cancer Study Group.

[1]  L. Holmberg,et al.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. , 1996, Journal of the National Cancer Institute.

[2]  J. Eyfjörd,et al.  TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis. , 1995, European journal of cancer.

[3]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[4]  E. Hovig,et al.  TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.

[5]  P. Jeffrey,et al.  Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.

[6]  S. Hirohashi,et al.  Association among p53 gene mutation, nuclear accumulation of the p53 protein and aggressive phenotypes in breast cancer , 1994, International journal of cancer.

[7]  K. Heimdal,et al.  Prognostic significance of TP53 alterations in breast carcinoma. , 1993, British Journal of Cancer.

[8]  U. Veronesi,et al.  p53 as an independent prognostic marker in lymph node-negative breast cancer patients. , 1993, Journal of the National Cancer Institute.

[9]  S. Hirohashi,et al.  p53 Mutations and c‐erbB‐2 Amplification in Intraductal and Invasive Breast Carcinomas of High Histologic Grade , 1993, Japanese journal of cancer research : Gann.

[10]  W. McGuire,et al.  Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. , 1993, Journal of the National Cancer Institute.

[11]  C. Theillet,et al.  p53 mutations occur in aggressive breast cancer. , 1992, Cancer research.

[12]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[13]  G. Merlo,et al.  Mutations in the p53 gene in primary human breast cancers. , 1991, Cancer research.

[14]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[15]  Y. Kitagawa,et al.  Significance of int-2/hst-1 coamplification as a prognostic factor in patients with esophageal squamous carcinoma. , 1991, Cancer research.

[16]  G. Ribeiro,et al.  The Christie hospital adjuvant tamoxifen trial--status at 10 years. , 1988, British Journal of Cancer.

[17]  S. Baylin,et al.  Gene amplification of c-myc and N-myc in small cell carcinoma of the lung. , 1986, Science.

[18]  J. Yokota,et al.  AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO , 1986, The Lancet.

[19]  H. Sather,et al.  Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.

[20]  D. Givol,et al.  Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. , 1985, The EMBO journal.

[21]  H. Third.  Hæmolytic Disease of the New-Born , 1958, Nature.

[22]  A. Børresen-Dale,et al.  TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Lane.  p53 and human cancers. , 1994, British medical bulletin.

[24]  V. Sheffield,et al.  Attachment of a 40-base-pair G + C-rich sequence (GC-clamp) to genomic DNA fragments by the polymerase chain reaction results in improved detection of single-base changes. , 1989, Proceedings of the National Academy of Sciences of the United States of America.